Ultrasound Contrast Agent Warnings Remain Boxed, But Less Monitoring Required
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects a citizen petition requesting removal of the boxed warning in Optison and Definity labeling, but the agency agrees to modified wording to eliminate certain monitoring requirements and include new data, despite misgivings about the quality of the postmarketing studies cited in the petition.
You may also be interested in...
Ultrasound Contrast Agents Should Drop Boxed Warning, Medical Society Tells FDA
Citizen petition by the International Contrast Ultrasound Society says updated safety data from recent meta-analysis makes black box unnecessary.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.